Data Presented at TCT Reinforce Edwards Lifesciences’ Commitment to Structural Heart Innovation
“The data at TCT on Edwards’ innovations underscore our commitment to scientific leadership and our focus to bring impactful and life-saving structural heart therapies to patients and physicians,” said
The data, including results from the groundbreaking EARLY TAVR and TRISCEND II trials, highlighted outcomes from studies that focused on previously understudied patient groups. The findings emphasized that timely treatment of structural heart disease not only enhances clinical outcomes and quality of life for patients, but also reduces long-term healthcare costs.
Transcatheter Aortic Valve Replacement (TAVR)
New data provided compelling evidence about TAVR, particularly for patients without symptoms but suffering from severe aortic stenosis, including:
- A meta-analysis highlightingthe importance of early intervention in asymptomatic severe aortic stenosis patients and reinforcing the results from the EARLY TAVR trial.
- A pooled analysis of RHEIA + PARTNER 3 data highlighting the efficacy and safety of Edwards TAVR in women.
- Insights into delays in care for aortic valve replacement (AVR), finding pre-procedural requirements contribute to TAVR patients waiting significantly longer than SAVR patients to access treatment.
- An assessment of the value of timely treatment of aortic stenosis, finding that intervening at earlier stages of cardiac damage helps save costs and healthcare resources.
Transcatheter Mitral and Tricuspid Therapies (TMTT)
Additionally, new evidence was presented on Edwards’ portfolio of transcatheter mitral and tricuspid repair and replacement therapies, reinforcing the strength of the company’s innovations beyond TAVR, including:
- Thetwo-year outcomes from the pivotal CLASP IID trial, showcasing sustained benefits of PASCAL in treating degenerative mitral regurgitation in a broad patient population.
- An analysis of thehealthcare resource utilization and costs associated with tricuspid regurgitation, highlighting the economic impact of timely intervention.
- One-year results from the TWIST global feasibility study, demonstrating promising outcomes for Innovalve in transcatheter mitral valve replacement, which was recently acquired by Edwards.
- Data from the PASTE registry, encompassing more than1,000 European patients treated with PASCAL in the tricuspid position, underscoring its safety and effectiveness.
About
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend the forward-looking statements contained in this release to be covered by the safe harbor provisions of such Acts. These forward-looking statements can sometimes be identified by the use of forward-looking words, such as “may,” “might,” “believe,” “will,” “expect,” “project,” “estimate,” “should,” “anticipate,” “plan,” “goal,” “continue,” “seek,” “intend,” “optimistic,” “aspire,” “confident” and other forms of these words and include, but are not limited to, statements made by
Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors as detailed in the company's filings with the
Edwards,
View source version on businesswire.com: https://www.businesswire.com/news/home/20241030713206/en/
Media Contact:
Investor Contact:
Source: